Globus Medical (GMED) Expected to Announce Earnings on Thursday
by Jessica Moore · The Cerbat GemGlobus Medical (NYSE:GMED – Get Free Report) is expected to release its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect Globus Medical to post earnings of $0.92 per share and revenue of $740.3410 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.
Globus Medical (NYSE:GMED – Get Free Report) last posted its quarterly earnings results on Tuesday, February 24th. The medical device company reported $1.28 earnings per share for the quarter, topping analysts’ consensus estimates of $1.06 by $0.22. Globus Medical had a net margin of 18.30% and a return on equity of 12.57%. The business had revenue of $826.42 million for the quarter, compared to analysts’ expectations of $803.29 million. During the same period in the prior year, the company posted $0.84 EPS. The business’s revenue for the quarter was up 25.7% on a year-over-year basis. On average, analysts expect Globus Medical to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.
Globus Medical Trading Down 0.7%
Shares of NYSE:GMED traded down $0.63 on Tuesday, reaching $89.97. 1,010,755 shares of the company were exchanged, compared to its average volume of 1,195,651. Globus Medical has a 1-year low of $51.79 and a 1-year high of $101.40. The firm has a market cap of $12.17 billion, a price-to-earnings ratio of 22.84, a price-to-earnings-growth ratio of 2.13 and a beta of 1.00. The company has a 50-day moving average of $90.09 and a 200-day moving average of $86.03.
Insider Buying and Selling
In related news, EVP Kelly Huller sold 20,000 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total value of $1,890,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 18.51% of the company’s stock.
Institutional Investors Weigh In On Globus Medical
Several hedge funds have recently modified their holdings of the company. Parallel Advisors LLC boosted its stake in shares of Globus Medical by 45.1% during the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after purchasing an additional 173 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Globus Medical by 74.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after purchasing an additional 197 shares during the last quarter. Mindset Wealth Management LLC boosted its stake in shares of Globus Medical by 1.9% during the 4th quarter. Mindset Wealth Management LLC now owns 10,715 shares of the medical device company’s stock worth $936,000 after purchasing an additional 200 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Globus Medical by 33.4% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 999 shares of the medical device company’s stock worth $57,000 after purchasing an additional 250 shares during the last quarter. Finally, Wealthspire Advisors LLC boosted its stake in shares of Globus Medical by 11.4% during the 4th quarter. Wealthspire Advisors LLC now owns 2,645 shares of the medical device company’s stock worth $231,000 after purchasing an additional 271 shares during the last quarter. 95.16% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on GMED shares. Citigroup reissued a “market perform” rating on shares of Globus Medical in a research note on Thursday, January 8th. Barclays increased their price objective on shares of Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Needham & Company LLC increased their price objective on shares of Globus Medical from $112.00 to $114.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Wells Fargo & Company raised shares of Globus Medical to a “strong-buy” rating in a research note on Wednesday, March 18th. Finally, Piper Sandler reissued an “overweight” rating and issued a $115.00 price objective (up from $90.00) on shares of Globus Medical in a research note on Thursday, January 8th. Three analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, Globus Medical currently has an average rating of “Moderate Buy” and an average price target of $104.36.
View Our Latest Analysis on Globus Medical
Globus Medical Company Profile
Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.
In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.